Jump to main content
Jump to site search

Issue 18, 2013
Previous Article Next Article

Chip-based liver equivalents for toxicity testing – organotypicalness versus cost-efficient high throughput

Author affiliations

Abstract

Drug-induced liver toxicity dominates the reasons for pharmaceutical product ban, withdrawal or non-approval since the thalidomide disaster in the late-1950s. Hopes to finally solve the liver toxicity test dilemma have recently risen to a historic level based on the latest progress in human microfluidic tissue culture devices. Chip-based human liver equivalents are envisaged to identify liver toxic agents regularly undiscovered by current test procedures at industrial throughput. In this review, we focus on advanced microfluidic microscale liver equivalents, appraising them against the level of architectural and, consequently, functional identity with their human counterpart in vivo. We emphasise the inherent relationship between human liver architecture and its drug-induced injury. Furthermore, we plot the current socio-economic drug development environment against the possible value such systems may add. Finally, we try to sketch a forecast for translational innovations in the field.

Graphical abstract: Chip-based liver equivalents for toxicity testing – organotypicalness versus cost-efficient high throughput

Back to tab navigation

Publication details

The article was received on 20 Feb 2013, accepted on 17 Apr 2013 and first published on 31 May 2013


Article type: Critical Review
DOI: 10.1039/C3LC50240F
Lab Chip, 2013,13, 3481-3495

  •   Request permissions

    Chip-based liver equivalents for toxicity testing – organotypicalness versus cost-efficient high throughput

    E. Materne, A. G. Tonevitsky and U. Marx, Lab Chip, 2013, 13, 3481
    DOI: 10.1039/C3LC50240F

Search articles by author

Spotlight

Advertisements